Alcohol Use Disorder Market - Global Forecast 2025-2032

The Alcohol Use Disorder Market is rapidly evolving as digital advancements, collaborative care models, and shifting regulatory dynamics converge to transform patient management and industry strategies. Comprehensive market analysis equips decision-makers with actionable insights into commercial opportunities, leading innovations, and emerging policy impacts across regions and segments.

Market Snapshot: Alcohol Use Disorder Market Size and Growth

The Alcohol Use Disorder Market expanded from USD 1.28 billion in 2024 to USD 1.37 billion in 2025 and is projected to progress at a CAGR of 6.76%, reaching USD 2.17 billion by 2032.

Scope & Segmentation

• Drug Classes: Acamprosate (effervescent tablet, oral tablet), Disulfiram (oral tablet), Naltrexone (injectable, oral tablet)
• Treatment Modalities: Behavioral therapy (cognitive behavioral therapy, family therapy, motivational enhancement therapy), Combined therapy (CBT with pharmacotherapy, MET with pharmacotherapy), Pharmacotherapy (injectable drugs, oral drugs)
• End Users: Home healthcare (home visits, telehealth), Hospitals (private, public), Rehabilitation centers (inpatient, outpatient), Specialty clinics (alcohol rehabilitation clinics, psychiatric clinics)
• Distribution Pathways: Hospital pharmacies (private, public), Online pharmacies (e-commerce websites, mobile apps), Retail pharmacies (chain, independent), Specialty pharmacies (AUD specialty, general specialty)
• Formulation Preferences: Dispersible tablet, effervescent tablet, injectable (intramuscular, intravenous, subcutaneous), oral tablet (immediate release, sustained release)
• Regions: Americas (North America: United States, Canada, Mexico; Latin America: Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (Europe: United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland; Middle East: United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel; Africa: South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)
• Key Companies: Alkermes plc, H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd., Viatris Inc., Sandoz International GmbH, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Lupin Limited, Cipla Limited

Key Takeaways for Senior Decision-Makers

• Integrated digital platforms are increasing the reach and uptake of treatments across remote and underserved regions, enabling scalable telehealth and mobile intervention frameworks.
• Regulatory momentum is supporting innovative reimbursement models and streamlined approval pathways, fostering faster market entry of novel therapies and digital health tools.
• Organizations are pursuing supply chain resilience, including dual-sourcing and regional manufacturing, to address trade fluctuations and tariff-related risks.
• Value-based care models are driving closer alignment between payer interests and outcome-focused provider strategies, reinforcing holistic and patient-centric approaches.
• Strategic alliances among pharmaceutical, biotech, and technology companies are accelerating research, driving innovation in long-acting formulations and digital augmentation.
• Regional differences in infrastructure, policy adoption, and local manufacturing are influencing entry strategies and investment priorities across Americas, EMEA, and Asia-Pacific.

Tariff Impact on the Alcohol Use Disorder Market

Recent United States tariff measures have heightened supply chain complexity and cost structures for treatment manufacturers, especially regarding imported pharmaceutical ingredients. Companies are proactively responding by exploring domestic partnerships and alternative logistics strategies to absorb potential price pressures. These adjustments aim to ensure business continuity and protect access for patients as the commercial and regulatory environment becomes increasingly nuanced.

Methodology & Data Sources

This report leverages a mixed-methods approach, combining primary interviews with clinical experts, regulators, and payers, alongside secondary research from peer-reviewed publications, regulatory disclosures, and company reports. Data triangulation was deployed to validate inputs and mitigate bias, supporting robust segmentation and regional analysis.

Why This Report Matters

• Provides in-depth guidance for aligning commercial strategies with digital and clinical innovations in the alcohol use disorder market.
• Equips stakeholders to anticipate regulatory, supply chain, and reimbursement shifts across multiple geographies and care models.
• Supports data-driven decision-making for portfolio diversification, market access, and investment prioritization in rapidly evolving therapeutic landscapes.

Conclusion

This analysis underscores the importance of adaptability and integrated collaboration in successfully navigating the evolving Alcohol Use Disorder Market. Acting on these insights positions organizations for sustainable competitive advantage and improved patient engagement as the sector continues its transformation.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.